obesity

Rona Therapeutics, a global leader in developing next-generation RNAi therapeutics, announced the successful submission of RN3161…

With ten other drugs in Phase III development by domestic companies, according to GlobalData’s Pharmaceutical Intelligence Center,…

The Obesity Gurukul program will aim to offer a structured and immersive learning experience for over 20,000 healthcare…

The ROGUE device is significant for countries like India as it offers a ‘living pharmacy’ that produces and adjusts diabetes…

The company plans to conduct dose optimization studies with a focus on the preferred formulation to inform the registration…

According to GlobalData, more than 190 million people currently live with type 2 diabetes and/or obesity in 7MM, and the numbers…

According to the KOLs interviewed by GlobalData, the diagnostic and management tools for obesity need to be updated and patients…

Zepbound is Eli Lilly’s new glucagon-like peptide-1/gastric inhibitory polypeptide (GLP-1/GIP) dual agonist, approved by the FDA…

Liraglutide is a drug-device combination for the treatment and management of Type 2 diabetes and obesity

The constrained supply of Wegovy and the necessity of ongoing obesity management support are key considerations